CompletedPhase 1/2

A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC

Taiwan10 participantsStarted 2014-10-22

Plain-language summary

This Phase I/II trial is to prove the efficacy and safety of AAV2-hAADC to treat patients with AADC deficiency.

Age range24 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. With a confirmed diagnosis of AADC, including cerebrospinal fluid analysis to show reduced levels of neurotransmitter metabolites, HVA and 5-HIAA, and higher L-Dopa, together with more than one mutation within AADC gene.
✓. Classical clinical characteristics of AADC deficiency, such as oculogyric crises, hypotonia and developmental retardation.
✓. The sick child has to be over 2 years old or a head circumference big enough for surgery.
✓. Participating patients must cooperate completely for all evaluations and examinations before, during and after the whole trial.
✓. Parents or guardians must sign to agree on this informed consent.

✕. Significant brain structure abnormality
✕. Patients with any health or neurological doubts that may increase the risk of surgery cannot join this trial. PI has the right to evaluate the feasibility of subjects for this trial based on his/her health condition.
✕. Since high-level neutralizing antibodies may disturb the therapeutic effect of gene therapy, patients with anti-AAV2 neutralizing antibody titer over 1,200 folds or an ELISA OD over 1 cannot be enrolled into this trial.
✕. Subjects enrolled in this clinical trial cannot take any medications that may affect this trial.

Evaluation of therapeutic effect

Timeframe: 12 months

NCT IDNCT01395641

SponsorNational Taiwan University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-18

Who can participate

Age range24 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. With a confirmed diagnosis of AADC, including cerebrospinal fluid analysis to show reduced levels of neurotransmitter metabolites, HVA and 5-HIAA, and higher L-Dopa, together with more than one mutation within AADC gene.
✓. Classical clinical characteristics of AADC deficiency, such as oculogyric crises, hypotonia and developmental retardation.
✓. The sick child has to be over 2 years old or a head circumference big enough for surgery.
✓. Participating patients must cooperate completely for all evaluations and examinations before, during and after the whole trial.
✓. Parents or guardians must sign to agree on this informed consent.

✕. Significant brain structure abnormality
✕. Patients with any health or neurological doubts that may increase the risk of surgery cannot join this trial. PI has the right to evaluate the feasibility of subjects for this trial based on his/her health condition.
✕. Since high-level neutralizing antibodies may disturb the therapeutic effect of gene therapy, patients with anti-AAV2 neutralizing antibody titer over 1,200 folds or an ELISA OD over 1 cannot be enrolled into this trial.
✕. Subjects enrolled in this clinical trial cannot take any medications that may affect this trial.